Cantor Fitzgerald Estimates FULC FY2026 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Fulcrum Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst K. Kluska expects that the company will earn ($1.04) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $10.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright restated a "neutral" rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Piper Sandler restated an "overweight" rating and set a $9.00 price objective (up from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. Leerink Partners upgraded shares of Fulcrum Therapeutics from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. Finally, Leerink Partnrs upgraded shares of Fulcrum Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $6.29.

Fulcrum Therapeutics Trading Up 1.0%

Fulcrum Therapeutics stock traded up $0.07 during midday trading on Wednesday, hitting $6.85. 247,184 shares of the stock were exchanged, compared to its average volume of 965,833. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $10.13. The stock has a market capitalization of $369.76 million, a price-to-earnings ratio of -22.10 and a beta of 2.41. The stock's 50-day simple moving average is $5.23 and its 200 day simple moving average is $4.28.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of FULC. Bank of New York Mellon Corp boosted its stake in Fulcrum Therapeutics by 2.3% during the fourth quarter. Bank of New York Mellon Corp now owns 141,873 shares of the company's stock worth $667,000 after buying an additional 3,126 shares during the period. Bailard Inc. purchased a new position in Fulcrum Therapeutics during the fourth quarter worth about $169,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Fulcrum Therapeutics by 176.8% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 367,594 shares of the company's stock valued at $1,728,000 after purchasing an additional 234,810 shares during the period. Intech Investment Management LLC boosted its stake in shares of Fulcrum Therapeutics by 74.9% in the fourth quarter. Intech Investment Management LLC now owns 30,499 shares of the company's stock valued at $143,000 after purchasing an additional 13,057 shares during the period. Finally, American Century Companies Inc. boosted its stake in shares of Fulcrum Therapeutics by 5.9% in the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company's stock valued at $567,000 after purchasing an additional 6,770 shares during the period. Hedge funds and other institutional investors own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.